Biografije predavača – Ass. dr Ana Cvetanović II Srpski senološki kongres

Biografije predavača – Ass. dr Ana Cvetanović II Srpski senološki kongres

Dr Ana Cvetanović rođena je 1983.godine u Nišu.

Medicinski fakultet u Nišu upisala je školske 2001/02. godine i diplomirala je 2007.godine, sa prosečnom ocenom 9,89

i ocenom 10 na diplomskom ispitu.

Učesnik je mnogobrojnih domaćih i inostranih kongresa. Dobitnik je brojnih stipendija.

Specijalistički ispit iz internističke onkologije položila je maja 2017.godine.

Dr Ana Cvetanović je zaposlena na  Medicinskom fakultetu Univerziteta u Nišu  u svojstvu Asistenta na Katedri za onkologiju

i Klinike za onkologiju, KC Niš, kao lekar specijalista internističke onkologije u odseku dnevne bolnice.

Doktorske akademske studije iz oblasti molekularne medicine upisala je školske 2013/14. godine

i trenutno se nalazi pred odbranom doktorske teze.

Autor je većeg broja naučnih i stručnih radova koji su saopšteni i objavljeni

u vodećim i značajnim domaćim i inostranim stručnim časopisi

 

ASS. DR ANA CVETANOVIĆ – REPREZENTATIVNE REFERENCE U ZADNJIH 10 GODINA

MONOGRAFIJE MEĐUNARODNOG ZNAČAJA

Cvetanovic A, Filipovic S, Vrbic S, Pejcic I, Popovic L. Side effects of cetuximab rash. In:Maddison RH.Haed and Neck cancer (1st edn). Editor: Maddison RH. Nova Science Publisher, New York, 2015, pp 123-138.

Cvetanovic A, Popovic L, Zivkovic N, Matovina-Brko G, Kostic M, Vrbic S, Pejcic I. Immune checkpoint inhibitors in the treatment of solid tumors:a new key in the hands of oncologists. In:Watanabe HS.Horizons in cancer research(volume 65). Editor: Watanabe HS. Nova Science Publisher, New York, 2017, 65-90.

NAUČNI RADOVI

Cvetanovic A, Vrbic S, Filipovic S, Pejcic I, Milenkovic D, Zivkovic N. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. JBUON 2013;18 (3): 641-646. (M23 IF 0.741)

Cvetanović A, Vrbić S, Filipović S, Pejčić I, Milenković D, Živković N, Petković I, Kostić M. Clinical benefit of Cetuximab and prognostic values of Cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analasys. JBUON 2014; 19(1):83-90. (M23 IF 0.741)

Pejcic I, Petkovic I, Vrbic S, Filipovic S, Balic M, Cvetanovic A. Mantle cell lymphoma-current literature overview. JBUON 2014; 19(2):342-349. (M23 IF 0.741)

Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, Vojinovic S, Marjanovic G, Savic V, Colic M. IL-17 and Glutamate Excitotoxicity in the Pathogenesis of Multiple Sclerosis. Scandinavian Journal of Immunology 2014;79(3):181-186. (M 23 IF 1.739)

Petkovic I, Krstic M, Pejcic I, Vrbic S, Stojnev S, Cvetanovic A, Balic M, Todorovic M. Renal Infiltration of Follicular Lymphoma. Turkish journal of hematology 2014;31(3):315-316. (M 23 IF 0.360)

Petrović D, Mihailović D, Petrović S, Živković N, Mijović Ž, Bjelaković B, Kostić M, Kesić Lj, Stanković A, Petrović M, Vučković I. Asymptomatic flow of Rosai-Dorfman disease. Vojnosanitetski pregled 2014; 71(8): 780-783. (M 24 IF 0.292)

Kostic M, Stojanovic I, Marjanovic G, Zivkovic N, Cvetanovic A. Deleterious versus protective autoimmunity in multiple sclerosis. Cell Immunol. 2015; 296 (2): 122-132. (M 23 IF 1.924)

Kocic B , Filipovic S, Vrbic S, Pejcic I, Rancic N, Cvetanovic A, Milenkovic D. Stressful life events and breast cancer risk: a hospital-based case-control study. JBUON 2015; 20(2): 487-491. (M23 IF 0.741)

Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G, Kostic M, Vicko F, Kocic B, Kolarov-Bjelobrk I. Young Age and Pathological Features Predict Breast Cancer Outcome-Report from a Dual Institution Experience in Serbia. JBUON 2015; 20(6):1407-1413 (M 23 IF 0.741)

Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D. High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells 2015; 7(11):1222–1232. (M 24)

Kostic M, Zivkovic N, Cvetanovic A, Stojanovic I, Colic M. IL-17 signalling in astrocytes promotes glutamate excitotoxicity: Indications for the link between inflammatory and neurodegenerative events in multiple sclerosis. Multiple Sclerosis and Related Disorders 2017;11: 12–17. (IF: 3.199 М22)

Krtinic D, Zivadinovic R, Jovic Z, Pesic S, Mihailovic D, Ristic L, Cvetanovic A, Todorovska I, Zivkovic N, Nedin Rankovic G, Stokanovic D, Zivadinovic B, Trandafilovic M, Apostolovic MA, Golubovic M, Zivadinovic A. Significance of the Ki-67 proliferation index in the assessment of the therapeutic response to cisplatin-based chemotherapy in patients with advanced cervical cancer. Eur Rev Med Pharmacol Sci 2018; 22(16):5149-5155. (M22 IF: 2.387)

Kostic M, Zivkovic N, Cvetanovic A, Stojanovic I. Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis. J Neuroimmunol 2018; 323:1-9. (IF: 2.655 M22)

Zivkovic N, Mihailovic D, Kostic M, Mijovic Z, Jovicic Milentijevic M, Cvetanovic A, Dencic T, Spasic M. Morphological, immunohistochemical, and morphometric analysis of myoepithelial tumors of the salivary gland. Anal Quant Cytol Histol 2016; 38(6):323-330. (IF: 0.454 M23)

Živković N, Mihailović D, Kostić M, Cvetanović A, Mijović Ž, Milentijević M, Denčić T. Markers of proliferation and cytokeratins in the differential diagnosis of jaw cysts. Ear Nose Throat J 2017; 96(9):376-383.  (IF: 1.010 M23)

Cvetanovic A, Filipovic S, Zivkovic N, Popovic L, Kostic M, Djordjevic M, Karanikolic A, Krtinic D.Ten years of using adjuvant trastuzumab in breast cancer in Serbia – Single institution experience. JBUON 2018; 23(2): 353-360 (IF: 1.766 M23)

Popovic L, Tomasevic Z, Stamatovic LJ, Markovic I, Matovina-Brko G, Cvetanovic A, et al. Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE. JBUON 2018; 23(2): 522-532. (IF: 1.766 M23)

Cvetanovic A, Pejcic I, Zivkovic N, Krtinic D, Kostic M, Popovic L. Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? JBUON 2019; 24 (2):516-521

UČEŠĆE U PROFESIONALNIM ORGANIZACIJAMA

Član Srpskog Lekarskog Društva (SLD)

Član Udruženja medikalnih onkologa Srbije (UMOS)

Član Evropskog udruženja medikalnih onkologa (ESMO)

Član Evropske onkološke škole (ESO)